Ash Life Sciences Ltd - Period Ending 2020-05-31

Ash Life Sciences Ltd - Period Ending 2020-05-31


Ash Life Sciences Ltd 10160574 false 2019-06-01 2020-05-31 2020-05-31 The principal activity of the company is that of calibration, maintenance and retail of pharmaceutical equipment Digita Accounts Production Advanced 6.26.9041.0 Software true 10160574 2019-06-01 2020-05-31 10160574 2020-05-31 10160574 core:RetainedEarningsAccumulatedLosses 2020-05-31 10160574 core:ShareCapital 2020-05-31 10160574 core:SharePremium 2020-05-31 10160574 core:CurrentFinancialInstruments 2020-05-31 10160574 core:CurrentFinancialInstruments core:WithinOneYear 2020-05-31 10160574 core:FurnitureFittingsToolsEquipment 2020-05-31 10160574 core:PlantMachinery 2020-05-31 10160574 bus:SmallEntities 2019-06-01 2020-05-31 10160574 bus:AuditExemptWithAccountantsReport 2019-06-01 2020-05-31 10160574 bus:FullAccounts 2019-06-01 2020-05-31 10160574 bus:SmallCompaniesRegimeForAccounts 2019-06-01 2020-05-31 10160574 bus:RegisteredOffice 2019-06-01 2020-05-31 10160574 bus:Director1 2019-06-01 2020-05-31 10160574 bus:Director2 2019-06-01 2020-05-31 10160574 bus:PrivateLimitedCompanyLtd 2019-06-01 2020-05-31 10160574 core:FurnitureFittings 2019-06-01 2020-05-31 10160574 core:FurnitureFittingsToolsEquipment 2019-06-01 2020-05-31 10160574 core:PlantMachinery 2019-06-01 2020-05-31 10160574 countries:AllCountries 2019-06-01 2020-05-31 10160574 2019-05-31 10160574 core:FurnitureFittingsToolsEquipment 2019-05-31 10160574 core:PlantMachinery 2019-05-31 10160574 2018-06-01 2019-05-31 10160574 2019-05-31 10160574 core:RetainedEarningsAccumulatedLosses 2019-05-31 10160574 core:ShareCapital 2019-05-31 10160574 core:SharePremium 2019-05-31 10160574 core:CurrentFinancialInstruments 2019-05-31 10160574 core:CurrentFinancialInstruments core:WithinOneYear 2019-05-31 10160574 core:FurnitureFittingsToolsEquipment 2019-05-31 10160574 core:PlantMachinery 2019-05-31 iso4217:GBP xbrli:pure

Company registration number: 10160574

Ash Life Sciences Ltd

Filleted Annual Report and Unaudited Financial Statements

for the Year Ended 31 May 2020

 

Ash Life Sciences Ltd

Contents

Balance Sheet

1 to 2

Notes to the Unaudited Financial Statements

3 to 7

 

Ash Life Sciences Ltd

(Registration number: 10160574)
Balance Sheet as at 31 May 2020

Note

2020
£

2019
£

Fixed assets

 

Tangible assets

4

20,184

23,086

Current assets

 

Stocks

5

3,000

3,200

Debtors

6

61,057

39,328

Cash at bank and in hand

 

95,340

51,061

 

159,397

93,589

Creditors: Amounts falling due within one year

7

(103,929)

(72,212)

Net current assets

 

55,468

21,377

Total assets less current liabilities

 

75,652

44,463

Provisions for liabilities

 

Deferred tax liabilities

 

(1,532)

(1,589)

Net assets

 

74,120

42,874

Capital and reserves

 

Called up share capital

100

100

Share premium reserve

15,000

15,000

Profit and loss account

59,020

27,774

Total equity

 

74,120

42,874

For the financial year ending 31 May 2020 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006. The option not to file the profit and loss account and directors’ report has been taken.

 

Ash Life Sciences Ltd

(Registration number: 10160574)
Balance Sheet as at 31 May 2020

Approved and authorised by the Board on 2 March 2021 and signed on its behalf by:
 


S M Hill
Director


A R Hill
Director

 
 

Ash Life Sciences Ltd

Notes to the Unaudited Financial Statements
for the Year Ended 31 May 2020

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
6 Office 1-34
The Hive
Beaufighter Road
Weston-Super-Mare
North Somerset
BS24 8EE

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

These financial statements are presented in Sterling (£).

Turnover recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in the profit and loss account, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Ash Life Sciences Ltd

Notes to the Unaudited Financial Statements
for the Year Ended 31 May 2020

Deferred tax is recognised on timing differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the company. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Deferred tax liabilities are presented within provisions for liabilities on the balance sheet.

Tangible assets

Tangible assets are stated at cost, less accumulated depreciation and accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation of tangible assets

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Plant and machinery

15% on reducing balance

Fixtures and fittings

25% on reducing balance

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

 

Ash Life Sciences Ltd

Notes to the Unaudited Financial Statements
for the Year Ended 31 May 2020

Creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year was 5 (2019 - 3).

 

Ash Life Sciences Ltd

Notes to the Unaudited Financial Statements
for the Year Ended 31 May 2020

4

Tangible assets

Furniture, fittings and equipment
 £

Plant and machinery
 £

Total
£

Cost or valuation

At 1 June 2019

3,229

34,188

37,417

Additions

-

850

850

At 31 May 2020

3,229

35,038

38,267

Depreciation

At 1 June 2019

1,615

12,716

14,331

Charge for the year

403

3,349

3,752

At 31 May 2020

2,018

16,065

18,083

Carrying amount

At 31 May 2020

1,211

18,973

20,184

At 31 May 2019

1,614

21,472

23,086

5

Stocks

2020
£

2019
£

Other stocks

3,000

3,200

6

Debtors

2020
 £

2019
 £

Trade debtors

58,814

34,798

Other debtors

2,243

4,530

Total current trade and other debtors

61,057

39,328

 

Ash Life Sciences Ltd

Notes to the Unaudited Financial Statements
for the Year Ended 31 May 2020

7

Creditors

Creditors: amounts falling due within one year

Note

2020
£

2019
£

Due within one year

 

Trade creditors

 

21,408

2,826

Taxation and social security

 

22,248

14,751

Corporation tax

 

20,039

16,030

Other creditors

 

40,234

38,605

 

103,929

72,212